Sei Lee
speaker
547 appearances
9 recordings
1 series
first heard Feb 2017
last heard Oct 2022
Sei Lee’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
And what it shows is that if your life expectancy is, for example, five, when it goes down to intensive blood pressure control, it's in the green because intensive blood pressure control has a life expectancy estimate of around 1.7 years.
And that's where the at 1.7 years, it's red to the left and then it's green to the right.
And for different types of interventions like statins for primary prevention, the time to benefit is at 2.5 years.
And so the nice thing is for a given life expectancy, for example, for at five years, what you see is that intensive blood pressure control, green, yes, it makes sense to do that.
Statins for primary prevention, yes, it makes sense to do that.
If you go further down and look at colorectal cancer screening, since that time to benefit is closer to 10 years and mammography is a little bit over 10 years, both of those interventions are in the red.
It doesn't make sense to do that because the time to benefit substantially exceeds the life expectancy of five years in this example.
and the life expectancy can move left or right depending on what somebody's life expectancy is.
And what we're working on now is making the life expectancy tie into some of the mortality calculators that are available on e-prognosis so that once you calculate the life expectancy, it can immediately link to this page and anchor the life expectancy as
given the patient's life expectancy as estimated as this, it's easy to see these interventions that are in green are the ones that would be recommended.
well i think the next thing that i'll be working on is i think quantifying the intensive glycemic control it's already on there but i think that's actually from just a single study so i think that's the next thing to try to quantify what um uh the the uh
time to benefit for intensive glycemic control.
But I'm certainly open to ideas.
I mean, I think bisphosphonates was really an idea that had been percolating and James really kind of took the ball and ran with.
I don't
it.
Yeah, I think it's probably more parallel than in bisphosphonates just because the pharmacokinetics of the anticoagulant medications.
Yeah, they're so
Yeah, when I took a look at that data, it does seem like the...
That's a really hard one because I think the benefits occur pretty quickly.
Showing 201–220 of 547 · page 11 of 28
← Previous
Next →